

Progress Report: Sri Lanka Clinical Trials Registry

SLCTR registration number: SLCTR/2025/040

Scientific title of trial: A Phase III, 52-week, Prospective, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center study, with a primary efficacy endpoint at 12 weeks, to determine the efficacy, safety, and tolerability of fixed doses of 15 mg bid and 30 mg bid of Evenamide as add-on in patients with documented Treatment-Resistant Schizophrenia, which is not adequately controlled by a stable therapeutic dose of the patient's current antipsychotic medication(s)

Date of commencement (enrolment of first participant): N/A

Progression: 6 months ☒ 1 year ☐ 2 years ☐ 3 years ☐
At completion ☐

1. Baseline data

Any changes to the trial design/ methodology/ protocol after commencement: No

Any changes to trial outcomes after commencement: No

2. Current status

Recruitment status: **pending**/ recruiting/ recruitment complete: follow up continuing/
recruitment complete: follow up complete/ recruitment suspended / recruitment
terminated

Number assessed for eligibility: None

Number recruited and allocated/randomized: None

Number allocated/randomized to each intervention/arm (please edit as relevant): NA

Arm 1: N/A

Arm 2: N/A

Losses/exclusions after allocation/randomization (please edit as relevant): NA

Arm 1: N/A

Arm 2: N/A

3. Trial output

Date of trial completion ("last patient, last visit"): Not yet achieved

Final sample size: 30

Summary of Interim/Final data (if available):

Not available yet

Abstract presentations of results at scientific meetings

Note: please include a URL link or scanned copy of the abstract

Title of Abstract	Full citation (please include authors, date, title of conference and place of presentation, page number of abstract).
NA	

Publications

Note: please include a URL link or scanned copy of the publication

Title of paper	Full citation (please include authors, title of journal, volume, issue and page numbers, and/or DOI)
NA	



.....
Name and signature of Responsible Registrant/
Principal Investigator: Prof. Shehan Williams

Date: 26 Mar 2026